


ERK-IN-3

Chemical Properties

CAS No. :	2055597-12-9
Formula:	C22H25ClFN7O2
Molecular Weight:	473.93
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	ERK-IN-3 (ASN007 free base) is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
Targets(IC50)	ERK
In vitro	ERK-IN-3 shows single-digit nanomolar antiproliferative activity that is selective for MAPK-pathway dependent cancer cell lines. ERK-IN-3 inhibits the phosphorylation of ERK1/2 substrates like RSK1, FRA1, and Elk1 in various cell lines.
In vivo	ERK-IN-3 (daily p.o.) inhibits tumor growth in multiple BRAF and KRAS mutant xenograft models in mice that was well tolerated at efficacious doses.

Solubility Information

Solubility	DMSO: 250 mg/mL (527.5 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.55 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.110 mL	10.5501 mL	21.1002 mL
5 mM	0.422 mL	2.110 mL	4.220 mL
10 mM	0.211 mL	1.055 mL	2.110 mL
50 mM	0.0422 mL	0.211 mL	0.422 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Sanjeeva PR, et, al. Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models. *Molecular Cancer Therapeutics*. 2018 Jan; 17(1).

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481